Commentary on cost-effectiveness of IV vs oral iron
Callie Berkowitz, Joshua Rivenbark · 2026
Read Commentary on cost-effectiveness of IV vs oral iron by Callie Berkowitz, Joshua Rivenbark (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13480114.txt.
Description
Berkowitz and Rivenbark, in a 2026 letter to the editor, question a cost-effectiveness verdict favouring intravenous iron. They respond to a modelling study by Wang and colleagues, which found intravenous iron good value against oral iron for iron deficiency anemia in women with heavy menstrual bleeding. The letter argues the model's assumptions stack the deck against the cheaper option.
The critics note the base case lets heavy bleeding continue untreated for 34 years, while a scenario adding bleeding treatment still delays it five years without explanation. They ask whether intravenous iron still wins if flow is cut promptly with effective options such as hormonal intrauterine devices. They also fault the oral iron schedule, which stops despite ongoing losses. Guidelines advise continued monitoring instead. And they warn that quality-of-life gains from treating bleeding itself are entangled with anemia gains.
Catalog record
| CREATOR | Callie Berkowitz, Joshua Rivenbark |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |